COVID-19 and Mucormycosis Coinfection: How Challenging It Is

Area of Science:

• Infectious Diseases
• Ophthalmology
• Critical Care Medicine

Background:

• Recent reports highlight a surge in rhinoorbital mucormycosis cases among COVID-19 patients in India.
• Diabetes mellitus is a significant risk factor for both severe COVID-19 and mucormycosis.
• Steroid administration is identified as a key precipitating factor for this opportunistic fungal infection.

Purpose of the Study:

• To outline the clinical presentation and management strategies for rhinoorbital mucormycosis in COVID-19 patients.
• To emphasize the importance of early diagnosis and prompt treatment.
• To highlight the role of glycemic control and judicious steroid use.

Main Methods:

• Review of clinical cases and existing literature on rhinoorbital mucormycosis in COVID-19 patients.
• Analysis of risk factors, including diabetes mellitus and steroid use.
• Discussion of diagnostic criteria and therapeutic interventions.

Main Results:

• Rhinoorbital mucormycosis is an angioinvasive fungal infection with a poor prognosis, especially in its rhinocerebral/rhinoorbitocerebral forms.
• Effective management relies on timely diagnosis and parenteral amphotericin B administration.
• Surgical interventions like debridement and exenteration may be necessary for advanced cases.

Conclusions:

• Judicious steroid use and strict glycemic control are paramount in managing diabetic COVID-19 patients at risk of mucormycosis.
• Prompt surgical debridement and antifungal therapy are essential for improving patient outcomes.
• Multidisciplinary management is crucial for addressing this complex and life-threatening condition.